Results 101 to 110 of about 42,521 (302)
British Journal of Clinical Pharmacology, EarlyView.Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le +5 more
wiley +1 more source
Discovery of peptides as key regulators of metabolic and cardiovascular crosstalk
Cell ReportsSummary: Peptides are fundamental regulators of metabolism, with several already developed as drugs, including glucagon-like peptide-1-based peptide therapeutics for diabetes and obesity.
Zeyuan Zhang, Katrin J. Svensson
doaj +1 more source
Cellular distribution and amount of chromogranin A in bovine endocrine pancreas [PDF]
, 1988 We determined the cellular distribution and the amount of chromogranin A in endocrine cells of bovine pancreas using a polyclonal antibody against bovine adrenomedullary chromogranin A. The relative amounts of chromogranin A in the different cells of the
Ehrhart, M. +3 more
core +1 more source
Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea
Chronic Diseases and Translational Medicine, EarlyView.Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy +3 more
wiley +1 more source
GLP2: An underestimated signal for improving glycaemic control and insulin sensitivity [PDF]
, 2016 Glucagon-like peptide 2 (GLP2) is a proglucagon-derived peptide produced by intestinal enteroendocrine L-cells and by a discrete population of neurons in the brainstem, which projects mainly to the hypothalamus.
Amato, A., Baldassano, S., Mul\ue8, F.
core +1 more source
Glucagon-Like Peptide-1 and Diabetes [PDF]
Experimental Diabetes Research, 2011 This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake.
openaire +2 more sources
Frailty and Cardiovascular Events as Determined by Body Composition: A Systematic Review
Chronic Diseases and Translational Medicine, EarlyView.Frailty phenotypes and risk of cardiovascular disease. Sarcopenic obese phenotype is associated with increased prevalence of cardiovascular risk factors and progression of metabolic syndrome, leading to cardiovascular events and cardiovascular mortality, while the Anorexic malnourished phenotype is associated with reduced prevalence of cardiovascular ...
Ishleen Oberoi +5 more
wiley +1 more source
Clinical Medicine Insights: Endocrinology and DiabetesObesity and diabetes mellitus are prevalent metabolic disorders that have a detrimental impact on overall health. In this regard, there is now a clear link between these metabolic disorders and compromised bone health.
Asif Ali, Peter R Flatt, Nigel Irwin
doaj +1 more source
BiomoleculesGlucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are related intestinal L-cell derived secretory products. GLP-1 has been extensively studied in terms of its influence on metabolism, but less attention has been devoted to GLP-2 in this
Asif Ali +5 more
doaj +1 more source
Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production [PDF]
, 2017 Glucagon is secreted from pancreatic a cells, and hypersecretion (hyperglucagonemia) contributes to diabetic hyperglycemia. Molecular heterogeneity in hyperglucagonemia is poorly investigated.
Albrechtsen, Reidar +28 more
core +3 more sources